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A B S T R A C T
Background
There are a number of studies that suggest a relationship between decline of melatonin function and the symptoms of dementia.
Objectives
The review assessed the evidence of clinical efficacy and safety of melatonin in the treatment of manifestations of dementia or cognitive
impairment (CI).
Search strategy
The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), The Cochrane Library, MEDLINE,
EMBASE, PsycINFO, CINAHL and LILACS were searched on 29 January 2008 using the terms: MELATONIN and N-ACETYL-
5-METHOXYTRYPTAMINE. The CDCIG Specialized Register contains records from all major health care databases (The Cochrane
Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources.
The search of January 2008 retrieved several studies for consideration by the authors.
Selection criteria
All relevant, randomized controlled trials in which orally administered melatonin in any dosage was compared with a control group for
the effect on managing cognitive, behavioural (excluding sleep), and/or affective disturbances of people with dementia of any degree
of severity.
Data collection and analysis
Two to three reviewers independently assessed the retrieved articles for relevance and methodological quality, and extracted data from
the selected studies. Statistically significant differences in changes in outcomes from baseline to end of treatment between the melatonin
and control groups were examined. Each study was summarized using a measure of effect (e.g. mean difference) and meta-analyses were
conducted when appropriate.
Main results
Three studies met the inclusion criteria. This review revealed non-significant effects from the pooled estimates of MMSE cognitive,
and ADAS-cognitive change scores. Individual study estimates for treatment effect demonstrated a significant improvement for 3 mg
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melatonin compared with placebo in behavioural and affective symptoms as measured by the ADAS non-cognitive scale in a study of
20 patients, and the Neuropsychiatric Inventory (NPI) following treatment with 2.5 mg/day (SR) melatonin, but not with 10 mg/day
(IR) melatonin in a larger study of 157 patients. The remainder of the treatment effects for affect, behaviour and activities of daily
living were non-significant.
Authors’ conclusions
There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of
dementia.
P L A I N L A N G U A G E S U M M A R Y
Insufficient evidence to support the effectiveness of melatonin for managing cognitive impairment
There are a number of studies that suggest a relationship between decline of melatonin function and the symptoms of dementia.
Evidence from three randomized, placebo controlled trials, designed to evaluate melatonin for sleep disorders associated with dementia,
found no evidence of efficacy for cognitive function, and evidence from a single small trial that theremay be some benefit for behavioural
problems.
B A C K G R O U N D
Melatonin, a naturally-occurring hormone secreted by the pineal
gland in the centre of the brain, was discovered by Lerner and col-
leagues at Yale University School of Medicine in 1958 (Wurtman
1989). It is biosynthesized from tryptophan via serotonin. It has a
number of effects relating to a variety of bodily functions. These
include circadian rhythmicity (physiological sleep onset and sleep-
wake cycles) and cyclic hormone release (Webb 1995); regulation
of the immune system (Maestroni 1993); and more recently dis-
covered anti-oxidant properties (Reiter 1995). In addition to the
brain, there are also melatonin receptors on cells of blood ves-
sels, ovaries and digestive system, though little is currently known
about their functions.
Since melatonin is a naturally occurring substance, it is not con-
sidered a drug in most countries. However, the safety of melatonin
products has not been definitely determined. Melatonin products
are regulated differently in several countries. In the United States,
melatonin falls under the Food and Drug Administration’s Di-
etary Supplement Health and Education Act in the category of
“other dietary supplements” and is “generally recognized as safe”.
In Canada, melatonin is included in the Natural Health Prod-
ucts Directorate of Health Canada. Melatonin is available for sale
in Canada, having met the specific licensing, manufacturing, la-
belling, and safety standards. In the European Union, melatonin
is considered a medicine or hormone and is available only by pre-
scription. In Australia, melatonin is an unregistered product under
the Therapeutic Goods administration. However, with a prescrip-
tion, it can be imported for use under the Personal Import Scheme
(Buscemi 2004). It should be noted that in situations where man-
ufacture and sale of melatonin is not regulated as for a drug, prepa-
rations may contain additives that have their own pharmacological
actions and potential side effects (e.g. some health food store mela-
tonin preparations are said to contain the same impurity which
causes eosinophilia-myalgia syndrome when found in tryptophan
preparations) (Williamson 1998).
Dementia is an acquired, persistent global impairment of intel-
lectual function. There are various diagnostic criteria based on
demonstration of acquired defects in more than one domain of
cognitive function, for example: language, memory, visuo-spatial
skills, emotion or personality, abstraction, calculation, judgment
or executive function. It is a common affliction, affecting some
8% of adults aged over 65 years, rising to 35% of those older than
age 85 years (CSHA 1994).
There are a number of factors suggesting a relationship between
decline of melatonin function and the deficits of dementia (CSHA
1994). These include:
• Decline of serum melatonin levels (Mishima 1994)
(to an even greater extent than in normal aging) and
the breakdown of normal circadian rhythmicity (Ghali
1995; Hopkins 1992) in patients with dementia. The
relationship between melatonin and circadian rhyth-
micity is well-established. The suprachiasmatic nuclei
(SCN) of the brain are generally accepted as the “seat”
of the circadian clock in humans (Moore 1992; Swaab
1985). Entrainment of the SCN (i.e. “setting” of the
biological clock) is, in large part, due to rhythmic re-
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lease of melatonin from the pineal gland (Dubocovich
1991).
• Disruption in sleep patterns in patients with demen-
tia (Prinz 1982), the relationship between melatonin
and sleep (Webb 1995), and the relationship between
sleep and cognitive function i.e. disrupted or insuffi-
cient sleep can contribute to significant difficulties with
tasks requiringmental concentration andmemory func-
tion (Downey 1987). This effect is thought to be even
more pronounced in people with pre- or co-existing
causes of cognitive impairment (Hopkins 1995).
• Correlation between typical areas of cerebral atrophy
in certain dementias (e.g. temporal lobes in Alzheimer’s
disease [AD]), and those areas containing melatonin
receptors (Dubocovich 1991; Fauteck 1995).
• Antioxidant and antiamyloidogenic properties of mela-
tonin (Pierrefiche 1995; Reiter 1994); and the known
involvement of oxidative and amyloid-mediated brain
damage in the pathogenesis of AD) (Varadarajan 2000).
Breakdown in normal function of melatonin-related brain func-
tions also may play a significant role in caregivers’ ability to care
for an individual with dementia. Specifically, problematic sleep-
related behaviours often precipitate the decision of families to in-
stitutionalize an elderly relative with dementia (Coffey 1994).
Generally, few adverse effects have been reported in human trials
in recent years (Andrade 2001; Seabra 2000; Shamir 2000). How-
ever, because of the many organ systems containing melatonin
receptors, effects could be far-reaching. Furthermore, a number
of older studies and animal data suggest a variety of possible side
effects including:
• Worsening of depression, sleep disturbance, weight loss
and an oral temperature decrease in depressed individ-
uals (Carman 1976); also supported by a finding in de-
pressed patients, but not in controls, of a longer du-
ration of the nocturnal period of active melatonin se-
cretion in winter than in summer (Wehr 2001). Fur-
thermore, because evening melatonin should produce a
circadian phase advance, it may worsen early morning
awakening.
• Decreased sex drive and infertility. In many mam-
mals, melatonin affects prolactin and gonadotropins (
Griffiths 1987; Smith 1987). This also appears to be the
case in humans, as high levels of melatonin have been
found inwomenwith hypothalamic amenorrhea (Berga
1988; Laughlin 1991) and in men with hypogonadism
(Karasek 1990; Puig-Domingo 1992). So too, exoge-
nous melatonin delays sexual maturation in experimen-
tal animals (Lang 1985; Rivest 1985), and high doses of
melatonin have been used in humans as a female con-
traceptive (inhibiting ovulation) in combination with
progesterone (Voordouw 1992).
• In mammals, melatonin may suppress insulin (
Rasmussen 1999) although a lack of effect on insulin
has also been found (Bizot-Espiard 1998). There is re-
cent evidence that exogenousmelatonin reduces glucose
tolerance and insulin sensitivity in post-menopausal
women (Cagnacci 2001).
• Melatonin has been found to increase retinal sus-
ceptibility to light-induced damage (Leino 1984;
Wiechmann 1992) but also to protect the retina from
oxidative damage (Siu 1999).
• Melatoninhas been reported tohave both vasoconstrict-
ing (Mahle 1997; Viswanathan 1997) and vasorelax-
ing properties (Cagnacci 2001a; Weekley 1995): it can
lower blood pressure (Chuang 1993; Tom 2001) and,
in animals, constrict cerebral and coronary arteries and
reduce cerebral blood flow (Capsoni 1995). The arterial
effect might account for several reports that melatonin
causes headache, although it has also been reported to
relieve headache (especially migraine) (Claustrat 1997;
Gagnier 2001). Vasoconstriction could also, theoreti-
cally, compromise cerebral circulation in older people
with atherosclerosis. However, another study suggests
melatonin may diminish the risk of hypoperfusion-in-
duced cerebral ischaemia by shifting the lower limit of
cerebral blood flow autoregulation to a lower pressure
level, improving the cerebrovascular dilatatory reserve,
and thuswidening the securitymargin (Regrigny 1998).
• At least one study reported increased seizures when
melatonin was given to neurologically compromised
children (Sheldon 1998), but elsewhere an anti-con-
vulsant and neuro-protective effect has been reported (
Munoz-Hoyos 1998).
• Exogenous melatonin (or its withdrawal) may trigger
or worsen manic episodes in susceptible individuals (
Leibenluft 1997), although it has also been found to
improve sleep and decrease severity of manic symptoms
in manic patients with treatment-resistant insomnia (
Bersani 2000; Robertson 1997).
• The preponderance of evidence suggests that mela-
tonin has anti-cancer properties in vitro (Hill 1988; Hu
1998), in animal studies (Kumar 2000) and in humans
(Lissoni 1994; Neri 1994). However, other studies have
found a lack of such effect (Panzer 1998) and there is
even at least one paper supporting a pro-neoplastic ef-
fect in a compound structurally similar to melatonin (
Malakhova 1986).
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• Melatonin appears to enhance immune function (
Maestroni 1993; Reiter 2000); this may have positive
clinical effects in illnesses such as cancer, butmayworsen
such autoimmune conditions as arthritis (Maestroni
2001).
O B J E C T I V E S
The objective was a systematic review of evidence relating to the
clinical efficacy and safety of melatonin in the treatment of man-
ifestations of dementia or cognitive impairment (CI).
M E T H O D S
Criteria for considering studies for this review
Types of studies
The review included all relevant unconfounded, randomized con-
trolled trials, published or unpublished, in which treatment allo-
cation was concealed and assessment of outcomes was blind. The
period of treatment exceeded one day. Studies were included irre-
spective of the language in which they were reported.
The first treatment period of crossover studies were includedwhere
appropriate, but since most conditions under evaluation were pro-
gressive, and in order to avoid carry-over effects, data from subse-
quent phases were excluded.
Types of participants
Included studies involved patients with dementia of any severity
or cognitive impairment. The diagnosis of dementia was based on
accepted criteria such as ICD, DSM (APA 1995) and NINCDS-
ADRDA (National Institute of Neurological and Communicative
Disorders and Stroke - Alzheimer’s Disease and Related Disorders
Association (McKhann 1984)). In the case of studies conducted
before the widespread availability or use of the accepted criteria,
the diagnosis was based on a comparable assessment using rating
scales. The diagnosis of cognitive impairment was usually based
on assessment using rating scales.
Types of interventions
Included trials assessed the effect of orally administered melatonin
in any dosage compared with placebo, or the effect of melatonin
compared with no treatment, for a minimum of one day, and with
a minimum of 24 hour follow-up.
Types of outcome measures
Relevant outcomes were cognitive, behavioural and/or affective,
function in activities of daily living, quality of life, caregiver stress,
morbidity, mortality and length of time to institutionalization.
Any trial with acceptable (i.e. objective, reproducible) measures
of the above was included. Sleep was not included as it is being
examined in another Cochrane review (Johnson 2001).
Side-effects and safety issues relevant to the use of melatonin were
assessed.
Search methods for identification of studies
See Cochrane Dementia and Cognitive Improvement Group
methods used in reviews.
The Specialized Register of the Cochrane Dementia and Cog-
nitive Improvement Group (CDCIG) was searched on 29 Jan-
uary 2008 for all years up to December 2005. This register con-
tains records from the following major healthcare databases: The
Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL
and LILACS, and many ongoing trial databases and other grey lit-
erature sources. The following search terms were used: melatonin
and N-ACETYL-5-METHOXYTRYPTAMINE.
The Cochrane Library, MEDLINE, EMBASE, PsycINFO and
CINAHL were searched separately on 29 January 2008 for
records added to these databases after December 2005 to January
2008. The search terms used to identify relevant controlled tri-
als on dementia, Alzheimer’s disease and mild cognitive impair-
ment for the Group’s Specialized Register can be found in the
Group’s module on The Cochrane Library. These search terms
were combined with the following search terms and adapted for
each database, where appropriate: melatonin and N-ACETYL-5-
METHOXYTRYPTAMINE.
The search of January 2008 retrieved several studies for consider-
ation by the authors.
On 29 January 2008, the Specialized Register consisted of records
from the following databases:
Healthcare databases
• The Cochrane Library: (2006, Issue 1);
• MEDLINE (1966 to 2006/07, week 5);
• EMBASE (1980 to 2006/07);
• PsycINFO (1887 to 2006/08, week 1);
• CINAHL (1982 to 2006/06);
• SIGLE (Grey Literature in Europe) (1980 to 2005/03);
• LILACS: Latin American and Caribbean Health Sci-
ence Literature (http://bases.bireme.br/cgi-
bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&base=LILACS&lang=i&fo
(last searched 29 August 2006).
Conference proceedings
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• ISTP (http://portal.isiknowledge.com/portal.cgi) (In-
dex to Scientific and Technical Proceedings) (to 29 Au-
gust 2006);
• INSIDE (BL database of Conference Proceedings and
Journals) (to June 2000);.
Theses
• Index
to Theses (formerly ASLIB) (http://www.theses.com/)
(UK and Ireland theses) (1716 to 11 August 2006);
• Australian Digital Theses Program
(http://adt.caul.edu.au/): (last update 24March 2006);
• Canadian Theses and Dissertations
(http://www.collectionscanada.ca/thesescanada/index-
e.html): 1989 to 28 August 2006);
• DATAD -Database of African Theses andDissertations
(http://www.aau.org/datad/backgrd.htm);
• Dissertation Abstract Online (USA)
(http://wwwlib.umi.com/dissertations/gateway) (1861
to 28 August 2006).
Ongoing trials
UK
• National Research Register (http://www.update-soft-
ware.com/projects/nrr/) (last searched issue 3/2006);
• ReFeR
(http://www.refer.nhs.uk/ViewWebPage.asp?Page=Home)
(last searched 30 August 2006);
• Current Controlled trials: Meta Register of Controlled
trials (mRCT) (http://www.controlled-trials.com/) (last
searched 30 August 2006) :
• ISRCTN Register - trials registered with a unique iden-
tifier
• Action medical research
• Kings College London
• Laxdale Ltd
• Medical Research Council (UK)
• NHS Trusts Clinical Trials Register
• National Health Service Research and Development
Health Technology Assessment Programme (HTA)
• National Health Service Research and Development
Programme ’Time-Limited’ National Programmes
• National Health Service Research and Development
Regional Programmes
• The Wellcome Trust
• Stroke Trials Registry
(http://www.strokecenter.org/trials/index.aspx) (last
searched 31 August 2006);
Netherlands
• Nederlands Trial
Register (http://www.trialregister.nl/trialreg/index.asp)
(last searched 31 August 2006);
USA/International
• ClinicalTrials.gov (http://www.ClinicalTrials.gov) (last
searched 31 August 2006) (contains all records from
http://clinicalstudies.info.nih.gov/);
• IPFMA Clin-
ical trials Register: www.ifpma.org/clinicaltrials.html.
The Ongoing Trials database within this Regis-
ter searches http://www.controlled-trials.com/isrctn,
http://www.ClinicalTrials.gov
and http://www.centerwatch.com/. The ISRCTN reg-
ister and Clinicaltrials.gov are searched separately. Cen-
terwatch is very difficult to search for our purposes and
no update searches have been done since 2003.
• The IFPMA Trial Results databases searches a wide va-
riety of sources among which are:
• http://www.astrazenecaclinicaltrials.com (seroquel,
statins)
• http://www.centerwatch.com
• http://www.clinicalstudyresults.org
• http://clinicaltrials.gov
• http://www.controlled-trials.com
• http://ctr.gsk.co.uk
• http://www.lillytrials.com (zyprexa)
• http://www.roche-trials.com (anti-abeta antibody)
• http://www.organon.com
• http://www.novartisclinicaltrials.com (rivastigmine)
• http://www.bayerhealthcare.com
• http://trials.boehringer-ingelheim.com
• http://www.cmrinteract.com
• http://www.esteve.es
• http://www.clinicaltrials.jp
This part of the IPFMA database is searched and was last updated
on 4 September 2006;
• Lundbeck Clinical Trial Registry
(http://www.lundbecktrials.com) (last searched 15 Au-
gust 2006);
• Forest Clinical trial Registry
(http://www.forestclinicaltrials.com/) (last searched 15
August 2006).
The search strategies used to identify relevant records in MED-
LINE, EMBASE, PsycINFO, CINAHL and LILACS can be
found in the Group’s module on The Cochrane Library.
Reference lists of retrieved articles (especially literature reviews)
were examined for additional trials and proceedings of relevant
conferences were searched.
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Data collection and analysis
Selection of trials
Titles and abstracts of citations obtained from the search were
examined by three reviewers (LJ, VD and DF) and obviously ir-
relevant articles discarded. In the presence of any suggestion that
an article described a relevant randomized controlled trial, it was
retrieved for further assessment.
Two authors (LJ, VD) independently assessed retrieved articles for
inclusion in the review according to the criteria above. Disagree-
ments were resolved by discussion, or if necessary referred to a
third author (DF).
Assessment of methodology and quality
The trial conduct and methodological quality were assessed by
both reviewers. Randomization and blind assessment of outcome
were threshold criteria for inclusion in the review. In addition,
whether participants were blind to their treatment allocation and
whether drop-out was judged to be serious enough to be a potential
source of bias was assessed for use in sensitivity analyses.
Concealment of allocation to treatment was rated by the following
three categories:
Category A (adequate) where the report described allocation of
treatment by: (i) some form of centralized randomized scheme,
e.g. having provided details of an enrolled participant to an of-
fice by phone to receive the treatment group allocation; (ii) some
form of randomization scheme controlled by a pharmacy; (iii)
numbered or coded containers, e.g. in a pharmaceutical trial in
which capsules from identical-looking numbered bottles are ad-
ministrated sequentially to enrolled participants; (iv) an on-site
or coded computer system, given that the allocations were in a
locked, unreadable file that could be accessed only after inputting
the characteristics of an enrolled participant; or (v) if assignment
envelopes were used, the report should at least specify that they
were sequentially numbered, sealed, opaque envelopes; (vi) other
combinations of described elements of the process that provided
assurance of adequate concealment.
Category B (intermediate) where the report described allocation
of treatment by: (i) use of a “list” or “table” to allocate assignments;
(ii) use of “envelopes” or “sealed envelopes”; (iii) stating the study
was “randomized” without further detail.
Category C (inadequate) where the report described allocation of
treatment by: (i) alternation; (ii) reference to case record numbers,
dates of birth, day of the week, or any other such approach; (iii)
any allocation procedure that was transparent before assignment,
such as an open list of random numbers or assignments.
Trials were included if they conformed to categories A or B; those
falling into category C were excluded.
Data extraction
Data were extracted from published reports or requested from
the first author when necessary. Summary statistics were required
for each trial and each outcome. For continuous data, the mean
change from baseline, the standard error of the mean change, and
the number of patients for each treatment group at each assessment
were extracted. Where changes from baseline were not reported,
the mean, standard deviation and the number of patients for each
treatment group at each time point were extracted if available.
The baseline assessment was defined as the latest available assess-
ment prior to randomization, but no longer than two months
prior.
In studies where a cross-over design was used, only data from the
first treatment phase after randomization were eligible for inclu-
sion.
Data analysis
The outcomesmeasured in clinical trials of dementia and cognitive
impairment often arise fromordinal rating scales.Where the rating
scales used in the trials have a reasonably large number of categories
(more than 10) the data were treated as continuous outcomes
arising from a normal distribution.
Summary statistics (sample size, mean and standard deviation)
were required for each rating scale at each assessment time for each
treatment group in each trial for change from baseline.
When change frombaseline results were not reported, the required
summary statistics were calculated from the baseline and assess-
ment time treatment group means and standard deviations. In
this case a zero correlation between the measurements at baseline
and assessment time were assumed. This method overestimates the
standard deviation of the change from baseline, but this conserva-
tive approach was considered to be preferable in a meta-analysis.
Themeta-analysis requires the combination of data from the trials.
The measure of the treatment difference for any outcome was the
weighted mean difference when the pooled trials used the same
rating scale or test to assess an outcome, and the standardisedmean
difference, which is the absolute mean difference divided by the
standard deviation, when they used different rating scales or tests.
Due to insufficient data, the following subgroup analyses were not
undertaken:
• Disease type:
- Alzheimer’s disease
- vascular dementia
- mixed Alzheimer’s disease and vascular dementia
- unclassified or other dementia
- cognitive impairment
• Duration of treatment:
- < 12 weeks
- > = 12 weeks
• Severity of dementia at baseline:
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- mild (MMSE > 17 or similar)
- moderate (MMSE 10 to 17 or similar)
- severe (MMSE < 10 or similar)
Sensitivity analyses will be performed with regard to:
• Blinding:
- double blind
- single blind
• Drop-out:
- unlikely to cause bias
- potentially leading to bias
• Imputation of missing dichotomous data:
- assuming missing outcomes were less favourable
- analysis as presented
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Three articles met the criteria for relevance and validity (Asayama
2003, Serfaty 2002, and Singer 2003). Two additional studies
seemed to meet the criteria for relevance and validity, but one
author could not be located for verification of study completion
(Eeles 2003), and one study was not executed because of lack
of funding (Haworth 2001). Three other studies were also ex-
cluded. The articles included in this review were all randomized
controlled trials published in 2002 or 2003. One study was a ran-
domized, double blind placebo-controlled two period crossover
study (Serfaty 2002), but the data following the cross-over period
have been omitted from this review in accordance with the pro-
tocol. One study was conducted in Tokyo, Japan and appeared
in the literature as a translated article in English (Asayama 2003),
The second study was conducted in London, UK (Serfaty 2002),
and the third in the United States (Singer 2003). The majority of
the participants were residents of a long term care facility, nursing
home or the geriatric ward of a hospital (Asayama 2003; Serfaty
2002; Singer 2003), while five were being cared for at home (
Serfaty 2002). Consent in all three of the studies was provided
by the participant’s caregiver or guardian. Two of the studies (
Asayama 2003; Serfaty 2002) also obtained the consent of the
participant. The total number of participants who were enrolled
in the studies was 210 and 200 completed the protocol.
Participants
The primary basis for selection of participants in all three studies
was the diagnosis of some type of dementia. One hundred sev-
enty seven participants in two of the studies had a diagnosis of
Alzheimer disease (AD) (Asayama 2003) or a NINCDS-ADRDA
diagnosis of probable AD (Singer 2003), which represents 80.09%
of the total participants in the three studies. In the third study,
the participants had to satisfy the APA 2004 (1994) criteria for
a clinical diagnosis of dementia (Serfaty 2002). Participants had
to be physically able to complete the study, which excluded those
who had a severe physical disease or problems. All of the stud-
ies required that participants be experiencing some type of sleep
disturbance. The Singer 2003 study included those with AD if
they averaged less than 7 hours of sleep per night (as documented
by wrist actigraphy), and were noted by the caregiver to experi-
ence two or more episodes per week of disturbed night-time sleep,
such as sleep latency, wandering, early wakening, and daytime
somnolence. Serfaty 2002 included those with a clinical diagnosis
of dementia who demonstrated at least two weekly incidents of
night-time agitated behavior as reported by the caregiver. Those
in Asayama 2003 study also were experiencing sleep disorders.
In all three studies, the Mini-Mental State Examination was ad-
ministered to establish the severity of dementia both at baseline
and the endpoint of the study. The meanMMSE scores of all par-
ticipants at baseline ranged from a low of 10.3 to a high of 14.6,
falling into the severe range of cognitive impairment (Tombaugh
1992).
Intervention
Before intervention with exogenous melatonin occurred, medi-
cations were stabilized in all three studies. In the Asayama 2003
study, beta-blockers were washed out for four weeks before the
study, while other drugs required by participants were maintained
provided that they did not affect the symptoms of AD. In the
Serfaty 2002 study, participants were either not taking hypnotic
medication, or were receiving the same dose of medication for at
least four weeks prior to entry into the trial. Psychotropic medi-
cation was not used during the study period. The participants in
the Singer 2003 study were excluded from the study if they had
been using investigational or unapproved medications within four
weeks of the screening visit.
Exogenous melatonin was administered to participants once a day
at the participant’s usual bedtime, or one hour prior, or at 20:30
hours. The intervention was administered by informal caregivers,
researchers, physicians or registered nurses with advanced prepa-
ration. Training was provided to all those who administered the
intervention. Dosage ranged from 3 to 10mg of immediate release
(IR) melatonin to 2.5 to 6 mg slow release (SR) melatonin. One
study (Singer 2003) divided participants into three groups: the
control group, a group which received 2.5 (SR) melatonin, and a
group which received 10 mg (IR) melatonin. A 3 mg melatonin
treatment was used in the Asayama 2003 study. Another study (
Serfaty 2002) administered 6 mg (SR) melatonin.
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Outcomes
The primary goal of each of these studies was to measure the
effects of exogenous melatonin on sleep disorders in participants
with cognitive dementia or AD. Primary outcomes in all three
studies weremeasured objectively usingwrist actigraphy.However,
this review focused on the evaluation of the secondary outcomes
including changes in cognition, behaviour, affect, and function in
activities of daily living. Adverse events associated with the use of
Melatonin were also examined.
Cognitive changes were measured by the Mini-Mental State Ex-
amination (MMSE) in all studies. Additionally, the cognitive sec-
tion of the Alzheimer’s Disease Assessment Scale (ADAS-Cogni-
tive) was employed by two studies (Asayama 2003; Singer 2003),
and the Clinical Dementia Rating Scale (CDR) was employed by
Asayama 2003. Behavioral and affective changes in the partici-
pants were measured using the Hamilton Depression Rating Scale
(Hamilton 1960) in Singer 2003, the Neuropsychiatric Inventory
(Cummings 1994) in Singer 2003, and the ADAS non-cognitive
scores (Rosen 1984) in Asayama 2003. Activities of daily living
(ADL) in the participants were measured in Singer 2003 using the
ADL Inventory (Galasko 1997). These tests and rating scales are
described in Table 1.
Table 1. Description of Assessment Scale Used in Included Studies
Mini-Mental State Examination (MMSE) used in Asayama 2003
and Singer 2003 study.
MMSE: Short, valid and reliable cognitive assessment tool that
can evaluate the severity of dementia and chronological changes
in functioning. Eleven task oriented items, key scale categories of
orientation, memory and attention. Total attainable score is 30
indicating healthy cognitive status. Concurrent validity supported
by correlations with the Weschler Adult Intelligence Scale ( r =
.776 with the Verbal Scale, p < .0001; r = .660 with Performance
Scale, p < .001 (Tombaugh 1992). Twenty-four hour retest (1
tester) r = .887, p < .0001; 24 hour retest (2 testers) r = .827, p <
.0001, 28 day retest r = .988, p < .0001(Folstein 1975).
Mini-Mental State Examination (MMSE) used in Asayama 2003
and Singer 2003 study.
ADAS-cognitive: Short valid measure of cognitive functional de-
cline associated with Alzheimer’s Disease (AD). Cognitive Scale
(11 items, task oriented, r = .989 p < .001, for interrater reliabil-
ity , test-retest reliability, r = .915, p < .001 : categories include
memory, language, recall, word finding difficulty, following com-
mands). Maximum score of 70 indicates marked cognitive symp-
toms of AD. Non-cognitive scale (10 items, 5 point scale: Inter-
rater reliability r=.947, p < .001, Test-retest reliability: r = .588,
p < .001: categories include depressed mood, distractability, un-
cooperative to testing, delusions, hallucinations, pacing, tremors,
decreased appetite) with maximum score of 50 indicating pres-
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Table 1. Description of Assessment Scale Used in Included Studies (Continued)
ence of construct. Significant correlation with the Sandoz Clinical
Assessment Geriatric Score (r = .668, df = 16, p < .01) and total
scale score, but not with noncognitive scale ( r = .252, df = 16, p
> .10) (Rosen 1984).
Clinical Dementia Rating Scale (CDR) used in Asayma 2003
study.
CDR:Valid and reliablemeasure of dementia and cognitive ability.
Categories include memory, orientation, judgment and problem
solving, community affairs, home and hobbies, and personal care.
Scale rating score ranges from 0 (healthy) to 3 (severe dementia).
Caregivers rate client ability from 1 to 9 (extreme debilitation).
Adequate correlations support the reliability of the instrument (
Hughes 1982).
Neuropsychiatric Inventory (NPI) used in Singer 2003 study. NPI: Valid measure of psychopathological behavior associated
with dementia. Ten dichotomous subscales: constructs of delu-
sions, hallucinations, depression, anxiety, agitation, apathy, irri-
tability/lability, disinhibition and euphoria. Concurrent validity
supported by results of correlation with BEHAVE-AD and the
Hamilton Depression Rating Scale (HDRS). Between rater, test-
retest, and internal consistency results support reliability of the
instrument. Data is obtained from caregivers. Higher score indi-
cates more severe psychopathology (Cummings 1994).
TheActivities ofDaily LivingQuestionnaire (ADL) used in Singer
2003 study.
ADL: Valid and reliable measure of functional decline associated
with Alzheimer’s disease . Inventory of 27 items ranging from 2
to 5 point scales. Test-retest reliability moderate to very good (K
statistic ranged from 0.4 to 0.75, p < .01. Spearman rank order
correlation coefficient between scaling levels of ADL and MMSE
scores ( R = 0.4 - 0.7, p < .001). Higher score indicates more
functional ability (Galasko 1997).
Categories: self-care, household care,
employment and recreation, shopping and money, travel, and
communication. Adequate reliability was supported by average
correlation coefficients of 0.86. Concurrent validity was
established by comparing the ADLQ with the Record of Indepen-
dent Living, a
previously validated measure of level of dependency in daily living
activities.
Negatively correlated with the Mini-Mental State Examination
and positively
correlated with the Clinical Dementia Rating Scale.
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Table 1. Description of Assessment Scale Used in Included Studies (Continued)
Hamilton Depression Rating Scale (HDRS) used in Singer 2003
study.
HRDS:Clinical utility demonstrated for screening and assessment
of depression. Primary psychometric research reported inter-rater
correlations ranging from 0.84 to 0.90, although interviewer sub-
jectivity may exist (Galasko 1960). Bagby 2004 reported adequate
convergent and discriminant validity, but inadequate content va-
lidity. Williams 2001 supported standardization of versions of the
scale and the 24 item symptom ratings to increase validity and
reliability.
Risk of bias in included studies
Essential principles of assessing methodological quality for the de-
velopment of systematic reviews include study methods of design,
allocation concealment, blinding of the interventions and out-
come, and assessment of attrition (Higgins 2008; Forbes 2003).
Selection bias can be addressed through a randomization process
that controls for potential confounding factors and comparability
of baseline states of the control and intervention groups. Perfor-
mance bias refers to the systematic differences in the care provided
to the participants in the comparison groups resulting from causes
other than the intervention. Decreasing these types of bias can
be achieved through single or double blinding techniques where
those receiving care and those providing care are unaware of the
assigned intervention, and the provision of training to those pro-
viding the intervention. Detection bias refers to systematic differ-
ences between the comparison groups in assessment of outcomes.
Blinding of outcome assessors limits detection bias. The length of
the study and characteristics of participants must also be consid-
ered in the examination of attrition bias as systematic differences
may exist in loss of participants between the comparison groups.
The three first authors of the included research studies were con-
tacted to obtain details of the random allocation and concealment
process referred to in the published articles. The key codes for
the double blind allocation sequence in all three studies were not
opened until after the data analyses were completed. Pharmaceuti-
cal staff in one study labeled the placebo andmelatoninmedication
through a random number treatment order allocation sequence (
Asayama 2003). Another study (Serfaty 2002) used a computer
generated numbering system to achieve randomized allocation to
treatment or control group. Serfaty 2002 also described the evalu-
ation process for the double blind technique employed to address
performance bias. Researchers, participants and care providers re-
ported they were unaware of the nature of the drug (melatonin
or a placebo) administered during the intervention phase of the
research. Singer 2003 reported that randomization and code de-
velopment was done at the Alzheimer’s Disease Cooperative Study
Unit (ADCS) at the University of California San Diego. Sealed
code breakers were delivered to all sites and collected following
study completion. A block randomization process was applied to
all ADCS study protocols. The three studies were rated as ade-
quate for design and allocation concealment to intervention; those
who assessed outcomes were also blind to allocation to the inter-
vention or control group. All authors provided information in the
publications or as requested by the reviewers detailing the proce-
dures used to train those administering the intervention and cog-
nitive and non-cognitive assessment instruments (Asayama 2003;
Serfaty 2002; Singer 2003). This information is summarized in
Table 2.
Table 2. Description of Methodological Quality of Included Studies
Control Confounders Attrition/Compliance
Asayama 2003 Randomized concealed allocation. Medications
stabilized, one study setting, no severe physical diseases and no
disorders that could cause sleep disorders other than AD. Baseline
level of cognitive impairment for placebo and intervention group
in moderate range of cognitive impairment according to MMSE
scores. Training was provided to those who were providing the
intervention and collecting data.
100% compliance with administration ofMMSE, ADAS-cog and
ADAS non-cog scales.
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Table 2. Description of Methodological Quality of Included Studies (Continued)
Serfaty 2002 Randomized concealed allocation. Medications sta-
bilized, informal caregivers received training for intervention in
two settings, training also provided for administration of Mini
Mental State Examination. Study exclusion criteria reported.
85% compliance with administration of MMSE.
Singer 2003 Randomized concealed allocation. None of the po-
tential covariates were significantly different between the groups
at baseline (age, duration of AD, sex, dementia severity, and years
of education). Training provided to those administering interven-
tion and assessment scales in long term care and private home
settings. Medications stabilized. Study exclusion criteria reported.
96% compliance with administration ofMMSE, ASAS-cog, NPI,
ADL, NPI
Exclusion criteria of the studies addressed potential confounding
factors such as unstable physical disease (Asayama 2003; Serfaty
2002; Singer 2003), depression (Serfaty 2002; Singer 2003) and
acute sleep disturbance (Asayama 2003; Singer 2003). Singer 2003
reported that none of the potential covariates were significantly
different between the groups at baseline (age, duration of AD,
sex, dementia severity, and years of education). The MMSE mean
baseline scores ranged from 10.3 to 14.6 as supported by data
obtained from the publication of Asayama 2003 and Singer 2003
and upon request from Serfaty 2002.
Medicationswere stabilized in all three studies.One study reported
that essential drug therapy was maintained, however, drugs such
as beta-blockers that may affect AD were eliminated four weeks
prior to the study (Asayama 2003). Singer 2003 identified that
participants were excluded from this study if: (1) they received
investigational or unapproved medications within four weeks of
the screening visit prior to the study, (2) psychotropic sleep med-
ication was discontinued within two weeks of the screening visit
prior to the trial, or (3) melatonin was administered within two
weeks of the screening visit.
The size of study samples varied across the research studies (see
Characteristics of Included Studies Table).However, attrition rates
were consistently low. One hundred percent compliance (n = 20 at
baseline and endpoint) with the Mini Mental State Examination
was achieved inAsayama 2003. Singer 2003 provided unpublished
data indicating a 96% participant compliance rate (n = 157 at
baseline, n = 151 at endpoint) with the administration of the
cognitive and non-cognitive assessment instruments used in the
study. Unpublished data prepared by Serfaty 2002 indicated an
85% compliance rate (n = 33 at baseline, n = 29 at endpoint) with
the administration of the Mini Mental State Examination.
See additional Table Description of Rating Scales used in the stud-
ies (Table 1).
Effects of interventions
Data were pooled from the studies based on critical appraisal of
the rationale for selecting the particular dose of melatonin in each
study. Although no consensus appeared to exist in the literature on
melatonin dosage, support was found for the efficacy, safety and
tolerance of melatonin across a pharmacologic dosage range of 1
- 10 mg in populations without dementia (Krinsky 2004). Singer
2003 also reported that therapeutic blood levelswere attained with
administration of 2.5 mg (SR) and 10 mg (IR) of melatonin in
pharmacokinetic studies conducted in elderly healthy subjects and
elderly subjects with AD.
Study outcomes are presented under the following headings:
Cognition
MMSE change scores from Asayama 2003 (melatonin 3 mg, 4
weeks at endpoint from baseline), Serfaty 2002 (melatonin 6
mg (SR), 2 weeks at endpoint from baseline), and Singer 2003
(melatonin 2.5 mg (SR), 7 weeks at endpoint from baseline) re-
vealed a non-significant effect for changing cognition (WMD
0.18, 95% CI -0.73, 1.10). Non-significant results for melatonin
treatment effect were also obtained from the pooled estimate
including the second pharmacologic treatment dose (melatonin
10 mg (IR), 7 weeks from baseline) from the Singer 2003, and
Asayama 2003, and Serfaty 2002 studies (WMD -0.14 95% CI -
1.14, 0.86). Further cognitive outcomes were measured using the
CDR Scale (Asayama 2003) and ADAS-Cognitive Scale (Asayama
2003, Singer 2003). Data, provided by Asayama 2003 upon re-
quest, indicated there were no mean CDR change differences be-
tween the melatonin and placebo groups. Analyses of the ADAS
cognitive change scores provided evidence for a significant effect
of 3 mg melatonin measured at 4 weeks from baseline (Asayama
2003) (WMD -4.60, 95% CI -7.81, -1.39). However, improve-
ment in the combined ADAS-cognitive scores was non-significant
for melatonin 3 mg (Asayama 2003) and melatonin 2.5 mg (SR)
(Singer 2003), measured at 4 and 7 weeks respectively from base-
line (WMD -2.64 95% CI -5.99, 0.71). Results measuring cogni-
tive improvement from the meta-analysis studies using melatonin
3 mg (Asayama 2003) and melatonin 10 mg (IR) (Singer 2003)
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were also non-significant (WMD -2.33 95% CI -6.40, 1.74).
Behavioral and affective
Two studies measured behavioral and affective change: Asayama
2003 used the ADAS non-cognitive scale, and Singer 2003 used
the Hamilton Depression Rating Scale (HDRS), and the Neu-
ropsychiatric Inventory (NPI). The three scales appeared to mea-
sure different constructs of behaviour and affect, therefore the
change scores could not be pooled. A significant treatment effect
for administration of 3mg of melatonin (Asayama 2003) was sup-
ported in the analyses of the ADAS non-cognitive change score
at 4 weeks from baseline (WMD -3.30 95% CI -4.85, -1.75),
and the NPI change score (Singer 2003) at the 7 week endpoint
measure of 2.5 mg (SR) melatonin (WMD -6.23 95% CI -11.93,
-0.53). Non-significant results were revealed between the Singer
2003 10 mg (IR) melatonin comparison groups at the 7-week
endpoint measure using the NPI scores (WMD 0.63 95% CI -
4.58, 5.84). When changes in the HDRS scores were compared
between those who receivedmelatonin and placebo, there were no
significant differences in change in scores from baseline to end of
treatment for administration of 2.5 mg (SR) melatonin (WMD
1.49 95% CI -0.29, 3.27) or 10 mg (IR) melatonin (WMD -0.20
95% CI -1.88, 1.48) (Singer 2003).
Activities of daily living
The ADL Inventory was used to rate items describing activities of
daily living in Singer 2003, the only study to measure functional
outcomes. Change scores for the control groups and intervention
groups were calculated following 7 weeks of treatment from base-
line. Non-significant results were revealed for treatment with 2.5
mg (SR) melatonin (WMD 0.33 95% CI -1.76, 2.42) and 10 mg
(IR) melatonin (WMD 0.49 95% CI -1.80, 2.78).
D I S C U S S I O N
No significant evidence was revealed in this review for the ef-
fect of melatonin administration on cognitive impairment asso-
ciated with dementia and AD. Individual study estimates for the
treatment effect demonstrated a significant improvement in be-
havioural and affective symptoms as measured by the ADAS non-
cognitive scale for 3 mg melatonin (Asayama 2003), and the NPI
following treatment with 2.5 mg (SR) melatonin (Singer 2003).
The remainder of the treatment effects for affect, behaviour and
activities of daily living were non-significant.
Several factors must be examined when considering the strength
of the conclusions.
Significant heterogeneity may exist within the study groups. The
type of dementia, length of time to institutionalization, and sever-
ity of the disease at the time of enrolment (only Singer 2003 re-
ported average duration of AD at time of enrolment as 4.9 years,
SD 3.0 years) may have influenced the outcomes. As participants
in the three studies were experiencing a severe degree of dementia,
the findings may not be applicable to milder forms of cognitive
impairment. Power analyses were not conducted in the individual
studies to determine if the sample sizes were large enough to de-
tect a difference if one existed. Although the endpoint sample size
(N=151) reported by Singer 2003 could be considered adequate
in the context of sleep-research studies, it is smaller than those ob-
tained in multicenter psychotropic medication trials. Therefore,
sample sizes were too small (n = 20, Asayama 2003; n = 29, Serfaty
2002; n = 151, Singer 2003) to undertake sensitivity and subgroup
analyses, and may have influenced the pooled estimate of the dif-
ferent interventions (i. e., melatonin 3mg, [Asayama 2003], mela-
tonin 6 mg [Serfaty 2002], and melatonin 10 mg, (IR) [Singer
2003]).
Other explanations for the non-significant treatment effects may
be related to the short time interval of the studies. Detection of
differences between treatment and control groups from baseline to
end of treatment may be difficult to detect due to small increments
of change and may require longer periods of time. However, all
studies incorporated random allocation to intervention, and blind
assessment of outcomes, thus meeting the validity inclusion crite-
ria for adequate design, allocation to intervention, performance,
detection, and attrition bias. MMSE baseline scores were deter-
mined to be in the moderate range and 80.09% of the total par-
ticipants in the three studies had a probable diagnosis of AD. Fur-
ther efforts were made in all three studies to control for potential
confounding variables through exclusion criteria for clinically sig-
nificant co-morbidity.
It should be noted that the primary goal of each of these stud-
ies was to measure the effects of exogenous melatonin on sleep
disorders in participants with cognitive dementia or AD. Sleep
disorders associated with the type or stage of dementia may have
influenced the outcome scores examined in this review. Asayama
2003 proposed that melatonin may indirectly affect cognitive and
non-cognitive function through an improved sleep wake rhythm.
Singer 2003 discussed the possible hypnotic effect of melatonin.
Several outcomes of interest were not addressed by the included
studies. Longer term studies are needed to examine outcomes such
as morbidity, mortality, and length of time to institutionalization.
Only one study (Serfaty 2002) alluded to caregiver stress, indi-
cating that as only 5 study participants resided with a carer at
home, statistical analysis of the carer’s sleep quality was not possi-
ble. Two studies collected data on adverse events (AE) associated
with the use of melatonin (Serfaty 2002; Singer 2003). Serfaty
2002 asserted there were no AEs, as the carers were asked to re-
port any AEs and none were reported. Singer 2003 provided de-
scriptive information regarding the occurrence and severity of re-
ported AEs from the 3 groups in the study. AEs in all 3 groups
were defined as “abnormal behavior, ache/pain, falls, fatigue, gas-
trointestinal distress, infection, respiratory/pulmonary symptom,
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skin/subcutaneous tissue, urinary symptoms” (p. 898) with an ad-
ditional notation of fatigue in the placebo group. Non-significant
effects were found for the mean number of AEs reported, severity
(rated from 1 [mild] to 3 [severe], seriousness (rated as 1[serious]
or 2 [not serious], and relatedness (rated as 1 [definitely related] to
5 [not related]. Based on an unadjusted P value (p = .04), Singer
2003 reported that AEs in the control group were more serious
than those in the melatonin 10 mg (IR) treatment group, and a
higher number of AEs were found in the ML 2.5 (SR) group than
in the ML 10 (IR) group.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to support the use of melatonin for
treatment of cognitive impairment associated with dementias and
AD.
Implications for research
Results may be strengthened by longitudinal studies that examine
the influence of melatonin over an extended time span. In addi-
tion, studies should not incorporate a crossover design due to the
potential residual effect following cross over. Single interventions
should be tested so that the effects can be clearly attributed to one
intervention. Several articles could not be included in the review
due to the inability to separate the effects of Bright Light Therapy
from Melatonin.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Asayama 2003
Methods Randomized controlled, double blind trial
4 weeks duration
Participants 3 males
17 females
Mean age: 79.2 (SD: 6.4).
Placebo group; n=9 (Mean age: 79.4 (SD: 5.3); 2 males, 7 females).
Melatonin treatment group: n=11 (Mean age: 78.9 (SD: 7.3); 1 male, 10 females)
All diagnosed with AD.
Setting: geriatric ward of a hospital from 2000-2002.
Diagnosed with AD with brain CT or brain MRI and EEG and DSM-1V and NINCDS-ARDRA.
Baseline moderate MMSE rating for both groups.
Interventions 1. Melatonin 3 mg
adminstered at 20:30 hours
2. placebo
Outcomes Cognitive and non-cognitive changes in CDR, MMSE, and ADAS-cognitive and non-cognitive (behav-
ioral and affective scores). Outcome measured at 4 weeks.
Notes PI: Dr. Kentaro Asayama, Department of Neuropsychiatry, Nippon Medical School. E-mail:
asayama@nms.ac.jp
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Serfaty 2002
Methods Randomized, controlled, double blind placebo-controlled two period
crossover design (2 weeks + 2 weeks)
Participants 16 males
9 females
Mean age: 84.2 (SD 7.6).
Diagnosed with DSM-1V .
Clinical Diagnosis: AD (18); MultiInfarct Dementia (4); Mixed Dementia (3).
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Serfaty 2002 (Continued)
Carers: multiple carers (20), single carer (5).
Setting: nursing home room (16), home setting (5), hospital setting (4).
Mean MMSE at baseline = 13.4 (SD 8.5).
Demographic description of four remaining participants was not published.
Interventions 1. Melatonin 6 mg (SR) given at participants’ usual bedtime.
2. placebo
Outcomes Cognitive change in MMSE.
Outcome measured at 2 weeks.
Notes PI:Dr.Marc Serfaty,Department of Psychiatry andBehavioral Sciences, Royal Free andUniversity College
Medical School, London
E-mail: mserfaty@rfc.ucl.ac.uk. Requested mean change score and MMSE demographics.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Singer 2003
Methods Randomized, controlled, double blind study, 7 weeks duration
Participants 157 in total
88 females
69 males
Mean age: 77.4 (SD 8.9)
NINCDS-ADRD diagnosis of probable AD.
Setting: Long Term care facility and private homes.
Extensive baseline data for all 3 groups on data abstraction tool.
Baseline moderate MMSE for all groups.
Interventions 1. Melatonin 2.5 mg (SR) or 10 mg (IR) given once a day 1 hour prior to usual bedtime.
2. placebo
Outcomes Cogitive and non-cognitive changes in MMSE, CDR, ADAS-cognitive and ADAS non-cognitive, NPI
behavioral and affective.
Outcome measured at 7 weeks.
Notes PI: Dr. Clifford Singer, Sleep and Mood Disorders Laboratory, Oregon Health and Science University. E-
mail: singer@ohsu.edu
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Singer 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Characteristics of excluded studies [ordered by study ID]
Baskett 2003 Study exclusion criteria included cognitive impairment as measured by score below 26 onMini-Mental
State Examination. Sleep quality was only outcome measured by the study.
Bourne 2006 Participants were not diagnosed with dementia or cognitive impairment.
Dowling 2008 Unable to separate effects of combined interventions of bright light therapy and melatonin.
Eeles 2003 No record of study completion.
Furio 2007 This melatonin for cognitive impairment study does not include those with dementia (only a 12% risk
of developing dementia).
Haffmans 2001 Unable to separate effects of combined interventions of bright light therapy and melatonin.
Haworth 2001 Reply from author on 20 February 2005 indicated that study did not proceed due to lack of funding.
Peck 2004 Participants were not diagnosed with dementia or cognitive impairment.
Riemersma 2004 Unable to separate effects of combined interventions of melatonin and bright light therapy.
Riemersma vanderlek 2005 Unable to separate effects of combined interventions of bright light therapy and melatonin.
Savaskan 2006 Literature review. The article does mention two placebo controlled trials, however they are not named
in the text.
Singer 2005 Sleep quality was only outcome measured by the study.
Tozawa 1998 Sleep waking and activity levels were measured concomitantly in the study.
Valontonin 2005 Sleep outcomes were the only outcome measured in the first study. The second study measured sleep
quality and activity levels for fairly healthy older adults living in rest homes.
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D A T A A N D A N A L Y S E S
Comparison 1. Melatonin vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 MMSE change scores at
endpoint (4 weeks, MLT 3
mg; 2 weeks, MLT 6 mg, 7
weeks, MLT 2.5 mg (SR) from
baseline
3 150 Mean Difference (IV, Random, 95% CI) 0.18 [-0.73, 1.10]
2 MMSE change scores at
endpoint (4 weeks, MLT 3 mg;
2 weeks, MLT 6 mg, 7 weeks,
MLT 10 mg from baseline
3 146 Mean Difference (IV, Random, 95% CI) -0.14 [-1.14, 0.86]
3 ADAS-cognitive change scores at
endpoint (4 weeks, 3 mg MLT;
7 weeks, 2.5 mg MLT) from
baseline
2 121 Mean Difference (IV, Random, 95% CI) -2.64 [-5.99, 0.71]
4 ADAS-cognitive change scores
at endpoint (4 weeks, 3 mg
MLT; 7 weeks, 10 mg MLT)
from baseline
2 117 Mean Difference (IV, Random, 95% CI) -2.33 [-6.40, 1.74]
Comparison 2. Melatonin vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Affective and Behavioral change
score in ADAS non-cognitive
at endpoint (4 weeks, 3 mg
MLT) from baseline
1 20 Mean Difference (IV, Fixed, 95% CI) -3.3 [-4.85, -1.75]
2 Neuropsychiatric and Behavioral
change score in NPI at
endpoint (7 weeks, 2.5 mg
MLT) from baseline
1 101 Mean Difference (IV, Fixed, 95% CI) -6.23 [-11.93, -0.53]
3 Neuropsychiatric and Behavioral
change score in NPI at
endpoint (7 weeks, 10 mg
MLT) from baseline
1 97 Mean Difference (IV, Fixed, 95% CI) 0.63 [-4.58, 5.84]
4 Hamilton Depression Rating
Scale change score at endpoint
(7 weeks, 2.5 mg MLT(SR)
from baseline
1 101 Mean Difference (IV, Fixed, 95% CI) 1.49 [-0.29, 3.27]
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5 Hamilton Depression Rating
Scale change score at endpoint
(7 weeks, 10 mg MLT) from
baseline
1 97 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.88, 1.48]
Comparison 3. Melatonin vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ADL change score at endpoint
(7 weeks, 2.5 mg MLT) from
baseline
1 101 Mean Difference (IV, Fixed, 95% CI) 0.33 [-1.76, 2.42]
2 ADL change score at endpoint
(7 weeks, 10 mg MLT) from
baseline
1 97 Mean Difference (IV, Fixed, 95% CI) 0.49 [-1.80, 2.78]
Analysis 1.1. Comparison 1 Melatonin vs placebo, Outcome 1 MMSE change scores at endpoint (4 weeks,
MLT 3 mg; 2 weeks, MLT 6 mg, 7 weeks, MLT 2.5 mg (SR) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 1 Melatonin vs placebo
Outcome: 1 MMSE change scores at endpoint (4 weeks, MLT 3 mg; 2 weeks, MLT 6 mg, 7 weeks, MLT 2.5 mg (SR) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asayama 2003 9 2.6 (1.7) 11 1.8 (3.2) 17.4 % 0.80 [ -1.39, 2.99 ]
Serfaty 2002 15 0.5 (4) 14 0 (4) 9.9 % 0.50 [ -2.41, 3.41 ]
Singer 2003 54 0.33 (2.8) 47 0.34 (2.7) 72.7 % -0.01 [ -1.08, 1.06 ]
Total (95% CI) 78 72 100.0 % 0.18 [ -0.73, 1.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
-10 -5 0 5 10
Favours placebo Favours melatonin
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Analysis 1.2. Comparison 1 Melatonin vs placebo, Outcome 2 MMSE change scores at endpoint (4 weeks,
MLT 3 mg; 2 weeks, MLT 6 mg, 7 weeks, MLT 10 mg from baseline.
Review: Melatonin for cognitive impairment
Comparison: 1 Melatonin vs placebo
Outcome: 2 MMSE change scores at endpoint (4 weeks, MLT 3 mg; 2 weeks, MLT 6 mg, 7 weeks, MLT 10 mg from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asayama 2003 9 2.6 (1.7) 11 1.8 (3.2) 20.8 % 0.80 [ -1.39, 2.99 ]
Serfaty 2002 15 0.5 (4) 14 0 (4) 11.8 % 0.50 [ -2.41, 3.41 ]
Singer 2003 50 -0.2 (3.4) 47 0.34 (2.7) 67.4 % -0.54 [ -1.76, 0.68 ]
Total (95% CI) 74 72 100.0 % -0.14 [ -1.14, 0.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
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Analysis 1.3. Comparison 1 Melatonin vs placebo, Outcome 3 ADAS-cognitive change scores at endpoint (4
weeks, 3 mg MLT; 7 weeks, 2.5 mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 1 Melatonin vs placebo
Outcome: 3 ADAS-cognitive change scores at endpoint (4 weeks, 3 mg MLT; 7 weeks, 2.5 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asayama 2003 9 -4.3 (3.6) 11 0.3 (3.7) 43.1 % -4.60 [ -7.81, -1.39 ]
Singer 2003 54 0.25 (5.4) 47 1.4 (4.9) 56.9 % -1.15 [ -3.16, 0.86 ]
Total (95% CI) 63 58 100.0 % -2.64 [ -5.99, 0.71 ]
Heterogeneity: Tau2 = 4.08; Chi2 = 3.19, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 1.4. Comparison 1 Melatonin vs placebo, Outcome 4 ADAS-cognitive change scores at endpoint (4
weeks, 3 mg MLT; 7 weeks, 10 mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 1 Melatonin vs placebo
Outcome: 4 ADAS-cognitive change scores at endpoint (4 weeks, 3 mg MLT; 7 weeks, 10 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asayama 2003 9 -4.3 (3.6) 11 0.3 (3.7) 45.5 % -4.60 [ -7.81, -1.39 ]
Singer 2003 50 0.97 (5.5) 47 1.4 (4.9) 54.5 % -0.43 [ -2.50, 1.64 ]
Total (95% CI) 59 58 100.0 % -2.33 [ -6.40, 1.74 ]
Heterogeneity: Tau2 = 6.79; Chi2 = 4.58, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.12 (P = 0.26)
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Analysis 2.1. Comparison 2 Melatonin vs placebo, Outcome 1 Affective and Behavioral change score in
ADAS non-cognitive at endpoint (4 weeks, 3 mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 2 Melatonin vs placebo
Outcome: 1 Affective and Behavioral change score in ADAS non-cognitive at endpoint (4 weeks, 3 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Asayama 2003 9 -4.1 (2.2) 11 -0.8 (1) 100.0 % -3.30 [ -4.85, -1.75 ]
Total (95% CI) 9 11 100.0 % -3.30 [ -4.85, -1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.16 (P = 0.000032)
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Analysis 2.2. Comparison 2 Melatonin vs placebo, Outcome 2 Neuropsychiatric and Behavioral change
score in NPI at endpoint (7 weeks, 2.5 mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 2 Melatonin vs placebo
Outcome: 2 Neuropsychiatric and Behavioral change score in NPI at endpoint (7 weeks, 2.5 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singer 2003 54 -6.4 (15.1) 47 -0.17 (14.1) 100.0 % -6.23 [ -11.93, -0.53 ]
Total (95% CI) 54 47 100.0 % -6.23 [ -11.93, -0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
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Analysis 2.3. Comparison 2 Melatonin vs placebo, Outcome 3 Neuropsychiatric and Behavioral change
score in NPI at endpoint (7 weeks, 10 mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 2 Melatonin vs placebo
Outcome: 3 Neuropsychiatric and Behavioral change score in NPI at endpoint (7 weeks, 10 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singer 2003 50 0.46 (11.9) 47 -0.17 (14.1) 100.0 % 0.63 [ -4.58, 5.84 ]
Total (95% CI) 50 47 100.0 % 0.63 [ -4.58, 5.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 2.4. Comparison 2 Melatonin vs placebo, Outcome 4 Hamilton Depression Rating Scale change
score at endpoint (7 weeks, 2.5 mg MLT(SR) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 2 Melatonin vs placebo
Outcome: 4 Hamilton Depression Rating Scale change score at endpoint (7 weeks, 2.5 mg MLT(SR) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singer 2003 54 -0.21 (4.6) 47 -1.7 (4.5) 100.0 % 1.49 [ -0.29, 3.27 ]
Total (95% CI) 54 47 100.0 % 1.49 [ -0.29, 3.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
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Analysis 2.5. Comparison 2 Melatonin vs placebo, Outcome 5 Hamilton Depression Rating Scale change
score at endpoint (7 weeks, 10 mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 2 Melatonin vs placebo
Outcome: 5 Hamilton Depression Rating Scale change score at endpoint (7 weeks, 10 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singer 2003 50 -1.9 (3.9) 47 -1.7 (4.5) 100.0 % -0.20 [ -1.88, 1.48 ]
Total (95% CI) 50 47 100.0 % -0.20 [ -1.88, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 3.1. Comparison 3 Melatonin vs placebo, Outcome 1 ADL change score at endpoint (7 weeks, 2.5
mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 3 Melatonin vs placebo
Outcome: 1 ADL change score at endpoint (7 weeks, 2.5 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singer 2003 54 -0.65 (6) 47 -0.98 (4.7) 100.0 % 0.33 [ -1.76, 2.42 ]
Total (95% CI) 54 47 100.0 % 0.33 [ -1.76, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
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Analysis 3.2. Comparison 3 Melatonin vs placebo, Outcome 2 ADL change score at endpoint (7 weeks, 10
mg MLT) from baseline.
Review: Melatonin for cognitive impairment
Comparison: 3 Melatonin vs placebo
Outcome: 2 ADL change score at endpoint (7 weeks, 10 mg MLT) from baseline
Study or subgroup Melatonin Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singer 2003 50 -0.49 (6.7) 47 -0.98 (4.7) 100.0 % 0.49 [ -1.80, 2.78 ]
Total (95% CI) 50 47 100.0 % 0.49 [ -1.80, 2.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
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WH A T ’ S N E W
Last assessed as up-to-date: 1 June 2008.
27Melatonin for cognitive impairment (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 June 2008 Amended Converted to new review format.
2 June 2008 New search has been performed An update search in January 2008 retrieved some new studies for consideration by
the authors; all studies identified have been excluded
H I S T O R Y
Protocol first published: Issue 3, 2002
Review first published: Issue 1, 2006
15 November 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
All correspondence: DF
Search for trials: VD
Obtaining copies of trial reports: VD
Selection of trials for inclusion/exclusion: LJ, VD, DF
Extraction of data: LJ, VD
Entry of data: LJ, VD
Interpretation of data analysis: DF, LJ, VD, DM
Drafting review: LJ, DF, VD, DM
-Contact editor: Rupert McShane
-Consumer editor: Toby Scott
This review was peer reviewed in January 2006
D E C L A R A T I O N S O F I N T E R E S T
None known
28Melatonin for cognitive impairment (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antioxidants [∗therapeutic use]; Cognition Disorders [∗drug therapy; etiology]; Dementia [∗drug therapy; etiology]; Melatonin [defi-
ciency; ∗therapeutic use]; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders [drug therapy]
MeSH check words
Humans
29Melatonin for cognitive impairment (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
